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Epicardial Adipose
Tissue as a Marker of
Coronary Artery Disease Risk*
Paolo Raggi, MD
Edmonton, Alberta, Canada
In an era when obesity and the metabolic syndrome are
growing to epidemic proportions, interest in visceral fat
accumulation as a marker of cardiovascular (CV) risk
appears most appropriate. In 1947, Jean Vague (1) first
reported that the android distribution of fat—central adi-
posity, as opposed to the gynoid phenotype: accumulation of
adipose tissue around the hips—was associated with in-
creased CV risk. It later became customary to assess obesity
based on a simple ratio of weight over height (i.e., body
mass index [BMI]), and several convincing publications
demonstrated over time the utility of this anthropometric
measure in estimating the CV risk associated with obesity (2).
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However, it also became obvious from population studies
that obesity per se is not necessarily associated with adverse
cardiometabolic parameters and that not all obese patients
present a similar risk profile (3). A further measure of
obesity achieved popularity with the publication of evidence
demonstrating that the waist-to-hip ratio was a better
predictor of CV disease than BMI (4). In this case, more
relevance was given to the android distribution of fat with
an assumption that a large abdominal girth equaled the
presence of a substantial accumulation of visceral adipose
tissue (VAT). However, with the implementation of com-
puted tomography and magnetic resonance imaging, inter-
esting data emerged to fully demonstrate the heterogeneity
of the obesity syndrome. In fact, a large waist circumference
may not necessarily indicate a large amount of VAT but
rather a substantial accumulation of subcutaneous fat (or a
combination of both); the “healthy obese phenotype” often
demonstrates a benign cardiometabolic profile. Hence, for
any BMI or waist-to-hip ratio, there could be a significant
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among individuals and a substantially different risk profile.
It is apparent, therefore, that simple anthropometric mea-
sures, although helpful as epidemiological tools, may fail to
completely inform us of the true CV risk of an individual.
Why the interest in visceral fat? Increased VAT has been
associated with an atherogenic profile defined by a combi-
nation of insulin resistance, hyperglycemia, hypertriglyceri-
demia with low high-density lipoprotein cholesterol, in-
creased small-dense low-density lipoprotein cholesterol, as
well as increased expression of inflammatory mediators (5).
More recently, attention turned to other regional deposits of
adipose tissue such as the intrathoracic deposits and, more
specifically, to the epicardial adipose tissue (EAT). In 2003,
Mazurek et al. (6) performed biopsies of the EAT and
subcutaneous adipose tissue of patients referred for elective
coronary artery bypass surgery and found a several-fold
higher expression of inflammatory markers in the EAT, but
not in the subcutaneous adipose tissue, of these individuals.
Furthermore, the EAT of patients awaiting coronary artery
bypass surgery showed dense T-lymphocyte, macrophage, and
mast cell infiltration that was completely absent in the subcu-
taneous fat of the same subjects. Similar results were reported
later by Baker et al. (7), Hirata et al. (8), and Cheng et al. (9),
although the last showed that the concentration of adiponectin
was reduced and that of several inflammatory cytokines was
increased to a larger extent in the VAT than EAT of patients
with established coronary artery disease. Several investigators
have suggested that the absence of a fascial plane separating the
adventitia of the coronary arteries from a very inflamed adipose
tissue milieu may favor the development of atherosclerotic
lesions via a paracrine effect more than—or in addition to—a
systemic inflammatory effect. In partial support of this theory
are the observations that EAT is associated with coronary
atherosclerotic plaques with characteristics of vulnerability
(10), severity of coronary artery disease demonstrated by
invasive and noninvasive angiography (11), and abnormal
myocardial perfusion imaging (12). Furthermore, segments of
the coronary arteries buried in a myocardial bridge (i.e., not in
direct contact with EAT) rarely, if ever, develop atherosclerotic
lesions. Two population-based studies in asymptomatic indi-
viduals have now shown an association between EAT, mea-
sured with noncontrast CT imaging of the heart, and incident
coronary events (13,14). In this issue of the Journal, Mahabadi
et al. (13) report on the 8-year follow-up of 4,093 subjects
enrolled in the Heinz Nixdorf Recall study conducted in the
Ruhr region of Northern Germany. During this period, the
investigators recorded 130 incident hard coronary disease
events (cardiac death and nonfatal myocardial infarction).
EAT, as seen in prior reports, was associated with traditional
cardiovascular risk factors, and patients with events had a larger
EAT volume than patients with no events during follow-up.
The highest quartile of EAT had a 5-fold greater risk of events
compared with those in the lowest quartile, and the association
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coronary artery calcium. In patients who underwent invasive
angiography following a nonfatal acute coronary syndrome
event, the thickness of EATwas greater around the areas hosting
a culprit intraluminal lesion. For several aspects, these results were
remarkably similar to those published by Ding et al. (14) in a
case-cohort substudy of MESA (the Multi-Ethnic Study of
Atherosclerosis). Ding et al. (14) reported a higher event rate
(147 events among 1,119 patients during 5 years of follow-up)
but included hard events as well as coronary revascularization as
endpoints. In reports by Ding et al. (14) and Mahabadi et al.
(13), EAT was associated with incident cardiac events inde-
pendent of traditional risk factors and anthropometric mea-
sures of obesity (waist circumference and BMI). In both
reports, there was a trend toward a stronger association of EAT
with events among women than men, although the difference
did not reach statistical significance. It should be noted that
Mahabadi et al. (13) measured EAT (i.e., fat located below the
parietal pericardium) in a fairly homogeneous Caucasian pop-
ulation, whereas Ding et al. (14) measured pericardial fat (i.e.,
epicardial plus paracardial fat) in a racially heterogeneous
sample, and this limits our ability to identify a threshold of
adipose tissue volume beyond which CV risk increases. What
can we conclude from these 2 studies and numerous previous
observations? Adipose tissue layered on the surface of the
myocardium is metabolically active and is associated with
coronary artery disease independent of risk markers. EAT can
be measured precisely with computed tomography and less
accurately with cardiac magnetic resonance and echocardiog-
raphy. Because EAT can be enlarged independent of anthro-
pometric measures of obesity, and given its predictive power, it
may be appropriate to start reporting this index of risk in
noninvasive imaging studies. Whether the volume of EAT can
be reduced with interventions and whether this will reduce risk of
events remains to be demonstrated. Nakazato et al. (15) showed
an increase in EAT volume in 71 patients who gained 5% of
their weight during 4 years of follow-up and 2% regression
of EAT in 54 patients who lost weight during the same period
of time. Melek et al. (16) reported a 3% regression of EAT in
194 women treated with intense statin therapy, whereas
Takase et al. (17) showed7% regression of VAT, with8%
ncrease in adiponectin in the absence of weight changes in 39
atients treated with ezetimibe. Clearly, this field remains open
or further investigation although the findings so far show once
gain the power of imaging.
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